A 13 Week, Double-Blind, Placebo-Controlled Phase 4 Trial of Pregabalin (CI-1008, 600 mg/Day) for Relief of Pain in Subjects With Painful Diabetic Peripheral Neuropathy.

Trial Profile

A 13 Week, Double-Blind, Placebo-Controlled Phase 4 Trial of Pregabalin (CI-1008, 600 mg/Day) for Relief of Pain in Subjects With Painful Diabetic Peripheral Neuropathy.

Completed
Phase of Trial: Phase IV

Latest Information Update: 12 May 2009

At a glance

  • Drugs Pregabalin (Primary)
  • Indications Diabetic neuropathies; Neuropathic pain
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 12 May 2009 Actual end date changed from 1 Nov 2005 to 1 Oct 2005 as reported by ClinicalTrials.gov.
    • 12 May 2009 Actual end date changed from 1 Nov 2005 to 1 Oct 2005 as reported by ClinicalTrials.gov.
    • 05 May 2007 Results data are available.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top